aspirin, clopidogrel

DRUG6 trials

Conditions

Acute Coronary SyndromesClopidogrel Low ResponsivenessClopidogrel Non-ResponsivenessCoronary Artery DiseaseFlow DiverterIschemic Heart DiseaseIschemic StrokePercutaneous Coronary Intervention

Phase 2

Tirofiban for Reduction of Thromboembolic Events in Endovascular Unruptured Aneurysm Repair

CompletedNCT06238115

Beijing Tiantan HospitalFlow Diverter, Stent-assisted Coiling, Thromboembolic Events +1

Start: 2024-03-04End: 2025-11-09Updated: 2025-12-11

Phase 4

Effects of Intensive Antiplatelet Therapy for Patients With Clopidogrel Resistance After Coronary Stent Implantation

CompletedNCT01094457

Shenyang Northern HospitalAcute Coronary Syndromes, Clopidogrel Low Responsiveness, Percutaneous Coronary Intervention

Start: 2009-03-31End: 2012-06-30Updated: 2012-06-14

Unknown Phase

Optimum Platelet Inhibition After Coronary Bypass Surgery

CompletedNCT00262275

Papworth Hospital NHS Foundation TrustIschemic Heart Disease

Start: 2002-07-31Updated: 2016-01-22

The Optimal Duration of Dual Antiplatelet Therapy After Implantation of Endeavor Stent

CompletedNCT00418860

Samsung Medical CenterCoronary Artery Disease

Start: 2006-09-30End: 2009-04-30Target: 1200Updated: 2011-08-11

The Comparison of Effects Between Increased Dose of Clopidogrel and Addition of Cilostazol

CompletedNCT00620646

Samsung Medical CenterClopidogrel Non-Responsiveness

Start: 2008-02-29End: 2009-02-28Target: 80Updated: 2009-02-12

Multi-center, Prospective, Cohort Study to Evaluate the Relationship of Stroke Recurrence and Anti-platelet Resistance in Ischemic Stroke Patients

CompletedNCT03823274

Yuhan CorporationIschemic Stroke

Start: 2019-04-01End: 2022-01-03Updated: 2022-10-12

Related Papers

Tirofiban for Reduction of TEAR: A Phase 2, Randomized, Open-Label, Blinded End Point, Controlled Trial.

2026-06-12

Molecular genomic and epigenomic characteristics related to aspirin and clopidogrel resistance